Seek Returns logo

ASND vs. CYTK: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ASND and CYTK, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ASND dominates in value with a market cap of 9.55 billion USD, eclipsing CYTK’s 3.74 billion USD by roughly 2.55×.

CYTK carries a higher beta at 0.81, indicating it’s more sensitive to market moves, while ASND remains steadier at 0.40.

ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while CYTK remains a standard domestic listing.

SymbolASNDCYTK
Company NameAscendis Pharma A/SCytokinetics, Incorporated
CountryDKUS
SectorHealthcareHealthcare
IndustryBiotechnologyBiotechnology
CEOMr. Jan Moller MikkelsenMr. Robert I. Blum
Price158.1 USD31.31 USD
Market Cap9.55 billion USD3.74 billion USD
Beta0.400.81
ExchangeNASDAQNASDAQ
IPO DateJanuary 28, 2015April 30, 2004
ADRYesNo

Performance Comparison

This chart compares the performance of ASND and CYTK over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ASND and CYTK based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • Neither ASND nor CYTK turned a profit—both carry negative P/E ratios of -24.59 and -6.03, underscoring continued losses that pressure their valuations.
  • ASND posts a negative forward PEG of -2.23, hinting at anticipated earnings decline, whereas CYTK at 10.57 has projections for stable or growing earnings.
  • Book value is underwater for both ASND (-44.27) and CYTK (-13.93), meaning liabilities exceed assets—signaling a critical solvency risk for both companies.
  • ASND and CYTK both consumed more free cash flow than they generated last year—P/FCF of -27.48 and -9.14, respectively—highlighting persistent liquidity pressure.
SymbolASNDCYTK
Price-to-Earnings Ratio (P/E, TTM)-24.59-6.03
Forward PEG Ratio (TTM)-2.2310.57
Price-to-Sales Ratio (P/S, TTM)22.92194.57
Price-to-Book Ratio (P/B, TTM)-44.27-13.93
Price-to-Free Cash Flow Ratio (P/FCF, TTM)-27.48-9.14
EV-to-EBITDA (TTM)-35.80-8.64
EV-to-Sales (TTM)23.82231.90
EV-to-Free Cash Flow (TTM)-28.55-10.89

Dividend Comparison

Neither ASND nor CYTK currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.

SymbolASNDCYTK
Dividend Yield (TTM)0.00%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ASND and CYTK, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas CYTK at 5.99 maintains a comfortable buffer of liquid assets.
  • Both ASND (debt-to-equity ratio -4.46) and CYTK (-2.97) exhibit negative shareholder equity—assets fall short of liabilities—signaling serious balance-sheet stress.
  • Both ASND and CYTK report negative interest coverage ratios (-3.72, -6.14), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
SymbolASNDCYTK
Current Ratio (TTM)1.045.99
Quick Ratio (TTM)0.715.99
Debt-to-Equity Ratio (TTM)-4.46-2.97
Debt-to-Assets Ratio (TTM)0.800.63
Interest Coverage Ratio (TTM)-3.72-6.14